FY2025 EPS Forecast for Zevra Therapeutics Lifted by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Zevra Therapeutics in a research note issued on Thursday, July 10th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of $1.58 for the year, up from their prior forecast of ($0.17). Cantor Fitzgerald has a "Overweight" rating and a $29.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Zevra Therapeutics' FY2026 earnings at $0.77 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same period in the previous year, the firm posted ($0.40) earnings per share.

ZVRA has been the subject of several other reports. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. HC Wainwright assumed coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Stock Up 2.8%

Shares of NASDAQ:ZVRA traded up $0.34 during midday trading on Monday, hitting $12.66. 1,494,049 shares of the company's stock were exchanged, compared to its average volume of 734,253. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The stock has a 50 day moving average price of $9.45 and a 200-day moving average price of $8.32. The company has a market cap of $692.25 million, a PE ratio of -6.66 and a beta of 1.97. Zevra Therapeutics has a 12 month low of $5.45 and a 12 month high of $13.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZVRA. Adage Capital Partners GP L.L.C. boosted its stake in Zevra Therapeutics by 462.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company's stock valued at $30,441,000 after acquiring an additional 3,001,000 shares during the last quarter. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $6,577,000. Readystate Asset Management LP raised its position in shares of Zevra Therapeutics by 924.6% in the first quarter. Readystate Asset Management LP now owns 683,032 shares of the company's stock valued at $5,116,000 after purchasing an additional 616,370 shares during the period. Woodline Partners LP raised its position in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after purchasing an additional 476,032 shares during the period. Finally, Velan Capital Investment Management LP raised its position in shares of Zevra Therapeutics by 121.7% in the first quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company's stock valued at $4,981,000 after purchasing an additional 365,000 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.